Efficacy of disitamab vedotin-based therapy in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis

Key Points

• Disitamab vedotin treatment reports improved efficacy in HER2-negative and HER2-low urothelial carcinoma patients, signaling a potential shift in treatment protocols.
• The analysis includes data from multiple studies that affirm the effectiveness of disitamab vedotin, showing a significant therapeutic benefit.
• Systematic review and meta-analysis assessed HER2 expression levels in locally advanced or metastatic urothelial carcinoma cases across various datasets and populations.
• Results support integrating disitamab vedotin in clinical practice for treating specific forms of urothelial carcinoma, though broader validation is warranted.